541 results on '"Stern, David F."'
Search Results
52. Supplementary Tables 1, 2, 4, and 5 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
53. Data from Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
54. Supplementary Table 3 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
55. Supplementary Table 6 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
56. Data from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
57. Supplementary Table 7 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
58. Supplementary Figures 1-11, Table 1, method and references from Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
59. Supplementary Methods and Figure Legends from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
60. Supplementary Figures 1 through 9 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
61. Supplementary Table S2 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
62. Supplementary Figure 4 from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
63. Supplementary Figure 1 from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
64. Data from Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
65. Data Supplement from Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
66. Data from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
67. Supplementary Figure Legend from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
68. Supplementary Figure 6 from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
69. Supplementary Figures S1-S6 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
70. Supplementary Figure 3 from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
71. Supplementary Figure 2 from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
72. Data from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
73. Supplementary Figure 5 from EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis
74. Supplementary Table and Figure Legends from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
75. Rad53 FHA Domain Associated with Phosphorylated Rad9 in the DNA Damage Checkpoint
76. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors
77. Molecular Cloning of the neu Gene: Absence of Gross Structural Alteration in Oncogenic Alleles
78. Type β Transforming Growth Factor: A Bifunctional Regulator of Cellular Growth
79. The Epidermal Growth Factor Receptor and the Product of the neu Protooncogene are Members of a Receptor Tyrosine Phosphorylation Cascade
80. Antiserum Raised Against a Synthetic Phosphotyrosine-Containing Peptide Selectively Recognizes p185 neu/erbB-2 and the Epidermal Growth Factor Receptor
81. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
82. ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
83. Gene expression profiling of ErbB receptor and ligand-dependent transcription
84. Global analysis of protein phosphorylation in yeast
85. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL
86. Carbazole Is a Naturally Occurring Inhibitor of Angiogenesis and Inflammation Isolated from Antipsoriatic Coal Tar
87. Activation of the Checkpoint Kinase Rad53 by the Phosphatidyl Inositol Kinase-like Kinase Mec1
88. Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain
89. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation
90. Identifying Modules of Cooperating Cancer Drivers
91. DNA Damage Regulates Chk2 Association with Chromatin
92. Regulation of CHK2 by DNA-dependent Protein Kinase
93. Interaction of Chromatin-associated Plk1 and Mcm7
94. Neuregulin-regulated gene expression in mammary carcinoma cells
95. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation
96. A role for DNA primase in coupling DNA replication to DNA damage response
97. Mutations in SPK1/RAD53 that specifically abolish checkpoint but not growth-related functions
98. ErbBs in mammary development
99. Specificity within the EGF family/ErbB receptor family signaling network
100. LIgands for ErbB-family receptors encoded by a neuregulin-like gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.